Effects of budesonide on P-glycoprotein expression in intestinal cell lines

British Journal of Pharmacology

Volumn 150, Issue 3, 2007, Pages 361-368

  Maier, A ^a   Zimmermann, C ^a   Beglinger, C ^a   Drewe, J ^a   Gutmann, H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ABCB1; Budesonide; Caco 2, LS180; Glucocorticoid receptor; Intestine; MDR1; P glycoprotein; PXR

Indexed keywords

BUDESONIDE; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 3A4; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; MESSENGER RNA; MIFEPRISTONE; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTESTINE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

BUDESONIDE; CACO-2 CELLS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; P-GLYCOPROTEIN; RECEPTORS, GLUCOCORTICOID; RECEPTORS, STEROID;

EID: 33846892518     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706992     Document Type: Article

References (36)

1. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M et al. (1998). Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95: 12208-12213.
2. Bhat UG, Winter MA, Pearce HL, Beck WT (1995). A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol 48: 682-689.
3. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ (2001). Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870.
4. Collett A, Tanianis-Hughes J, Warhurst G (2004). Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 68: 783-790.
5. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287.
6. Dilger K, Schwab M, Fromm MF (2004). Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10: 578-583.
7. Fromm MF (2003). Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 (Suppl 2): 6-9.
8. Geick A, Eichelbaum M, Burk O (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276: 14581-14587.
9. Hidalgo IJ, Raub TJ, Borchardt RT (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96: 736-749.
10. Hofer KN (2003). Oral budesonide in the management of Crohn's disease. Ann Pharmacother 37: 1457-1464.
11. Juliano RL, Ling V (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
12. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG (2002). The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 16: 1509-1517.
13. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82.
14. Klotz U, Schwab M (2005). Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57: 267-279.
15. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG (2002). Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64: 943-948.
16. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A et al. (2004). Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127: 26-40.
17. Lin JH, Chiba M, Chen IW, Nishime JA, deLuna FA, Yamazaki M et al. (1999). Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 A and p-glycoprotein induction. Drug Metab Dispos 27: 1187-1193.
18. Panwala CM, Jones JC, Viney JL (1998). A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161: 5733-5744.
19. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ (2001). Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268: 6346-6358.
20. Pedersen KB, Vedeckis WV (2003). Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines. Biochemistry 42: 10978-10990.
21. Perloff MD, Von Moltke LL, Greenblatt DJ (2004). Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 34: 133-150.
22. Pfrunder A, Gutmann H, Beglinger C, Drewe J (2003). Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 55: 59-66.
23. Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG (1995). Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ 6: 1321-1332.
24. Schwab M, Klotz U (2001). Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 40: 723-751.
25. Sheppard KE (2002). Nuclear receptors. II. Intestinal corticosteroid receptors. Am J Physiol Gastrointest Liver Physiol 282: G742-G746.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
27. Smoak KA, Cidlowski JA (2004). Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125: 697-706.
28. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H et al. (2001). Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299: 164-170.
29. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738.
30. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y et al. (2001). Transcriptional control of intestinal cytochrome P-4503A by 1á,25-dihydroxy vitamin D3. Mol Pharmacol 60: 1399-1406.
31. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N et al. (1992). Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252.
32. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R et al. (2000). Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68: 345-355.
33. Wright AP, Zilliacus J, McEwan IJ, Dahlman-Wright K, Almlof T, Carlstedt-Duke J et al. (1993). Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 47: 11-19.
34. Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M (2001). Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 29: 145-151.
35. Zhou C, Tabb MM, Sadatrafiei A, Grun F, Blumberg B (2004). Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 32: 1075-1082.
36. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J (2005). Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 33: 219-224.